HIGHLIGHTS
- who: Qiushang Ji from the University of Porto, Portugal Switzerland have published the research: Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patient, in the Journal: (JOURNAL) of 31/08/2021
- what: The authors demonstrated that selexipag effectively improves WHO FC, 6MWD, and NT-proBNP, and was accompanied with better risk assessment without unreported side effects.
- how: Categorical data are compared using Fisher`s exact test. *P and amplt 0.05 between two groups. u2020 Data missing for some subjects.
SUMMARY
To date, the rationale . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.